Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.
Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high costs—often exceeding $1,000 per month—put them out of reach for many Americans whose ...